The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2020 | Genomics in myelofibrosis: practical guidelines for its use in clinical practice
Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses practical guidelines for the use of genomics in the treatment and management of myelofibrosis. Specifically discussed is the growing understanding of the landscape of prognostic mutations and the implications of this on treatment approaches including transplantation, and the use of targeted agents such as ruxolitinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
